Currently trading in the sub-penny range Propanc Health Group Corp. (PPCH) is likely the MOST UNDERVALUED BIOTECH stock across all markets.
With it's revolutionary peer reviewed cancer fighting drug PRP set for FDA regulatory process and the company actively soliciting Big Pharma in marketing efforts for potential licensing suitors, now is the time to buy shares!
Propanc (PPCH) is a cutting edge small biotech company based in Melbourne Australia who has developed a unique drug for the treatment of many types of cancer specifically targeting the process of metastasis. Cancer becomes far more serious and difficult to treat when it spreads to new locations within the body, this process is called metastasis.
What makes this new drug particularly important is that there are currently no FDA -approved drugs specifically targeting metastatic cancer, yet if metastasis could be halted most cancers would not be serious or fatal.
Propanc (PPCH) has developed a blend of naturally-occurring chemicals - PRP - that has now been shown to specifically block or reverse the processes that lead to the development of metastases and their ability to grow and spread further. These chemicals, or proenzymes, are normally manufactured by the pancreas.
Consider these exciting facts:
-In tests on cancer cells, PRP was able to halt the growth of cancer cells and cause these cells to undergo cell death.
-PRP was also able to cause malignant cancer cells to transition to more harmless cell types, no longer cancerous.
-these changes in cancer cells caused by PRP indicate that PRP may be highly effective in the treatment of metastatic cancers of many types. The results of these studies have been published in the peer-reviewed scientific journal Cellular Oncology.
-currently, there are no drugs approved for the targeting of metastatic cancer, placing Propanc (PPCH) in a strong position as the regulatory process moves forward.
- Propanc (PPCH) has filed global patent applications as well with the US Patent and Trademark Office, seeking approval of pending claims covering its novel product candidates, PRP and PRP-DCM.
-Propanc (PPCH) will be meeting with the FDA, to file for a Investigational New Drug (IND) prior to undertaking formal IND-enabling studies to support entry into Phase I human trials.
-Propanc (PPCH) has also commenced marketing efforts to potential licensing suitors, such as Big Pharma, Biotechs and Specialty Pharma Companies. These licensing partners who may be interested in licensing PRP as part of their oncology portfolio. Such licensing deals can often fast track potential earnings and revenue for early stage companies.